Archive | October, 2021

Last Day to Save

28 Oct

By Karen Deyo, Director of Investor Research, Israel BD, LSN

Life Science Nation’s next event, Digital RESI November, is fast approaching, and with early bird pricing ending this Friday, now is the time to register if you haven’t already. Whether a first-time attendee or a familiar face, RESI offers many opportunities to advance your startup. From panels featuring investors and strategic partners providing insights into how they are best approached, to entrepreneurs sharing their fundraising success stories, to service providers providing tips on how to navigate the complex path to market based on decades of experience, RESI provides opportunities for seasoned entrepreneurs and first-time founders.

What makes RESI truly unique is the match-based partnering infrastructure and free education around how to make the system work in your favor to connect with partners who are a fit for your product and stage of development. RESI’s powerful ability to bring together the early-stage life science ecosystem and to provide companies and investors with a way to tailor their meetings to ensure the most effective use of their time makes it stand out at a time when virtual events are a dime-a-dozen. Don’t believe us? Check out the list of attending investors below. The partnering system is open, so make sure to register soon!

Confirmed Digital RESI November Investors and Strategic Partners

As of October 28

RESI-NOV-Banner-3050x-1050

Applications Due Tomorrow

28 Oct

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

claire

The Innovator’s Pitch Challenge (IPC) is a highlight at Life Science Nation events, with innovative startups in life science and healthcare pitching to investors in a live Q&A format, providing feedback, practice, and for some, valuable connections that lead to deals. The IPC returns to Digital RESI November 16-18 and there is one day left to apply at the extended deadline!

If you are involved with a company in active fundraising mode and want to boost your exposure, gain valuable feedback from investors and industry experts, and secure meetings with investors who have a genuine interest in your technology, you do not want to miss out on the last IPC of 2021!

Below is a list of companies who have been accepted as finalists – conference attendees will be able to vote for their favorite pitch.

 

RESI-NOV-Banner-3050x-1050

Pain Points and the Power of Perseverance: The MindLab Story

28 Oct

By Rory McCann, Marketing Manager & Conference Producer, LSN

Larry Raoul James is no stranger to challenge, rejection, and powering through. His company, MindLab has developed a pain management therapeutic designed to prevent tolerance, dependence, and addiction in patients, while sustaining current efficacy standards. With recent endorsement from the US Army Medical Research & Development Command (a connection made through a recent RESI conference), Larry and the MindLab team are not slowing down. Despite the challenges associated with bringing novel therapeutics to market, they are working hard to meet a persistent and growing need for safe alternatives to pain medication.

Listen to a recent interview with Larry on the MindLab journey.

Tomorrow is the last day to sign up for Digital RESI November 16-18 at early bird rates. Sign up today to get started and save $100!
RESI-NOV-Banner-3050x-1050

Hot Investor Mandate: Listed Pharmaceutical Company Actively Seeking Global Novel Therapeutics in Anti-Infection & Oncology

28 Oct

A listed pharmaceutical company with 5 Billion of assets under management. After over 2 decades of arduous efforts, the firm has become a high-tech pharmaceutical health industry cluster that covers manufacturing, R&D, and sales in the pharmaceutical area. The firm is open to global R&D partnerships and investment opportunities.

The firm has focused interest in Traditional Chinese Medicine granules, finished drugs, pharmaceutic adjuvants, active pharmaceutical ingredients, medical devices, medical and health management services. In addition, the firm pays special attention to novel therapeutic innovations in sepsis, anti-infection, and oncology area.

The firm has no specific company or management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Venture Arm of Global Advisory Firm Invests in Seed Stage Medical Device, Diagnostics, and Digital Companies Across the Globe

28 Oct

The venture arm of a global advisory dedicated to healthcare with practices across regulatory and clinical affairs, market access and HEOR strategy consulting, and investment banking.  The firm uses its experience in the industry to invest in promising early stage companies developing medical devices, diagnostics or digital health technologies. The firm invests at the seed stage, and serves as a strategic investor as much as a financial investor, using industry knowledge and contacts to help companies grow. The firm will generally invest between $250K-1M in companies that have some proof of concept and IP. The firm will invest globally.

The firm invests in medical device, diagnostics and digital health companies. While the firm is generally agnostic to subsector and indication, it tends to avoid companies with a long time to exit. In addition, while the firm is willing to consider all types of medical devices, they are less likely to invest in PMA devices at this stage.

The firm is a very active investor, and thus takes a board seat, even if just an observer position, to lend their expertise. The firm can lead or coinvest, but tends to coinvest, and can help build a syndicate with their contacts.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: USA-Based Genetic Screening Company Interested in Investing and Partnering with Molecular Diagnostics Companies, Investing Up to $30M

28 Oct

A company specializing in genetic screens, headquartered in the USA is interested in nearly all types of molecular diagnostics and the technologies that support them. The firm is willing to consider co-development or investment, and will generally invest in later stages (Series B or later), which may lead to an acquisition at a later stage of development. For strategic research collaboration, for example, the company may be willing to commit funds anywhere from US$5-30M, and will look at companies all across the globe, but has focused thus far on US, Europe, Asia and Israel.

While the firm thus far has focused solely on genomics, the company is interested in nearly all types of molecular diagnostics. Currently, their indications of interest include mental health, oncology, and women’s health, with screens in ob/gyn and breast and ovarian cancers, in addition to prostate cancer screens. For now, the firm prefers to stay within those indications of interest. In addition to new technologies in molecular diagnostics (e.g., next-generation sequencing, multi-omics), the company is also interested in sample preparation (such as sequencing technologies) and liquid-based tests.

The firm is looking to partner with or invest in early stage companies that either have some market traction, or have significant scientific data or an award or grant from the NIH or other similar institutions. The company also looks for companies that have a solid IP position for their technology.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Main Investment and Operation Vehicle of a USA-Based Angel Group Invests in All Life Science Sectors, Helps Companies With Chinese Market Expansion

28 Oct

A main investment and operation vehicle of an angel group founded was formed on the basis of investing in passionate early-stage entrepreneurs developing novel technologies. The firm’s areas of interest include AI, big data, pharmaceuticals, healthcare, wearable devices, etc. The firm has invested in academic spin-offs from Harvard and MIT as well.

The firm has three sub-entities, including an offline incubator, in order to find valuable US high-tech startups, conduct rigorous screening, help them with accelerated growth and expand into the Chinese market, as well as providing exit strategy guidance.

The firm is interested in a wide range of life science areas. The firm will look at Therapeutics, Medical Devices, Digital Health, and Diagnostics. The firm seeks to invest in early-stage companies, within therapeutics, the firm will look at stages before phase I.

The firm has no specific company or team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

← Older Entries